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Objective: To develop and test a decision-support tool for prioritizing new competing Health Technologies (HTs) after their assessment using the mini-HTA approach.
Methods: A two layer value/risk tool was developed based on the mini-HTA. The first layer included 12 mini-HTA variables classified in two dimensions, namely value (safety, clinical benefit, patient
impact, cost-effectiveness, quality of the evidence, innovativeness) and risk (staff, space and process of care impacts, incremental costs, net cost, investment effort). Weights given to these variables
were obtained from a survey among decision-makers (at National/Regional level and hospital settings). A second layer included results from mini-HTA (scored as higher, equal or lower), which
compares the performance of the new HT (in terms of the abovementioned 12 variables) with the available comparator. An algorithm combining the first (weights) and second (scores) layers was
developed to obtain an overall score for each HT, which was then plotted in a value/risk matrix. The tool was tested using results from the mini-HTAs for three new HTs (Surgical Robot, Platelet Rich
Plasma, Deep Brain Stimulation).
Results: No significant differences among decision-makers were observed as regards the weights given to the 12 variables, therefore, the median aggregate weights from decision-makers were
introduced in the first layer. The dot plot resulting from the mini-HTA presented good power to visually discriminate between the assessed HTs.
Conclusion: The decision-support tool developed here makes possible a robust and straightforward comparison of different competing HTs. This facilitates hospital decision-makers deliberations on the
prioritization of competing investments under fixed budgets.
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The background knowledge that underpins hospital-based
health technology assessment (HTA) is the same as that used for
national/regional HTA. However, the tools and the data required
for making a decision with regard to the introduction of a given
new health technology (HT), its timing frame, and the weights
given to the different criteria used in the assessment may differ
from one setting to another. Hospital decision makers need a
quick and tailored answer to make a decision on the acquisi-
tion of specific health technologies. Traditional time-consuming
HTA reports may not suit their needs and constraints. Addition-
ally, the relative importance given to the different dimensions in
the assessment at hospital level may vary from that at national or
regional level in the healthcare system. Indeed, whereas safety,
efficacy/effectiveness, and cost-effectiveness are the main cri-
teria incorporated in a traditional national/regional assessment;
safety, organizational impact, efficacy, and budget impact are
the dimensions most frequently present in hospital level HTA
(6). Strategic considerations, such as the innovativeness of the
HT in a teaching hospital and the investment effort may also
play a prominent role in the final decision at hospital level. In
brief, hospital-based HTA combines relevant information on
the clinical outcomes coming from scientific evidence, and the
unique organizational and economic implications of a new HT
at hospital level, thus providing shorter and more timely HTA
reports to hospital managers.
The first publication discussing the need to create multi-
disciplinary committees in hospitals that would assess the ap-
propriateness of acquiring new HTs is dated 1979 (15), and it
was not until 1986 that the experience of these committees was
formally described (16). These early committees used some of
the core elements of the HTA process, but did not apply cur-
rent standards of HTAmethodology. Nowadays, HTAwithin the
hospital setting is widespread including valuable experiences in
Canada, Denmark, Italy, and Spain.
The first tool aimed at implementing HTA at hospital level
was designed by the Andalusian HTA Agency (AETSA, Spain)
back in 1999 (4). Nowadays, one of the probably most well-
known tools in this respect is the so-called “mini-HTA” devel-
oped by the Danish Centre for Health Technology Assessment
(DACEHTA) in 2005 (7). Mini-HTA is a management and de-
cision tool edited as a check-list with several questions grouped
into four relevant HTA aspects (technology, patient, organiza-
tion, and economy), allowing for short answers to questions,
and with the potential to be adapted to local objectives, deci-
sion criteria, and time schedules (7).
Mini-HTA is useful for the local assessment of innovative
HTs and in the standardization of decision-making processes
regarding the introduction of newHTs, making them both trans-
parent and accountable. Under fixed budget conditions, once the
different HTs have been assessed using the mini-HTA, hospital
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Table 1. Value and Risk Variables.
Dimensions and variables Definition
VALUE
Safety Patient potential undesirable effects with the new HT.
Clinical benefits Efficacy/effectiveness of the new HT, based on scientific evidence, compared with current available HTs.
Patient impact Ethical, psychological and quality of life issues associated with the new HT.
Cost-effectiveness Availability (and results if available) of published economic evaluation studies.
Quality of Evidence Quality of scientific evidence of the new HT, using available quality scales (eg. SIGN, GRADE; Oxford EBM)
Innovativeness Level of novelty of the new HT
RISK
Staff requirements Hospital staff requirements (training, expertise. . .) for the new HT
Physical space impact Space requirements for the new HT to be operational
Process of care impact Impact of the new HT on the organization of healthcare services and/or work dynamics and flows within the hospital.
Incremental cost Increase in the cost-per-case when using the new HT, compared with cost-per-case with available alternative
Net cost Difference between costs-per-process with the new HT and current level of funding from payers for the available alternative.
Investment effort Impact of the acquisition of the new HT on overall hospital’s/department annual budget for HTs investment.
decision makers face the challenge of how to best prioritize
resource allocation among potentially very different HTs. A
tool that visually compares HTs and uses mini-HTA criteria
to inform decision making could be of valuable assistance. In
addition, this tool should be able to adequately compare and
discriminate among HTs once assessed.
The objective of this study is twofold. First, to convey the
development of a new decision support tool to aid hospital
decision makers in their investment decisions regarding new
competing HTs. Second, to test whether this tool visually dis-
criminates among competingHTs according to their attributable
risks and benefits.
METHODS
We developed a computer program to plot the risk and value
scores of new HTs that had previously been assessed with the
mini-HTA. It is a two-layer software program based on (i) the
different weights given to the mini-HTA variables, and (ii)
the results from the comparative assessment of the new HT
and the available alternative.
From the twenty-six questions in the Danish mini-HTA tool
(7), we selected those nine deemed most relevant from a hos-
pital’s point of view based on the relative interest shown by
clinicians and managers when commissioning mini-HTA re-
ports to our unit during the past 3 years. We added three more
variables as a result of incorporating cost-effectiveness, inno-
vativeness, and investment effort concerns coming from these
same clinicians and managers at the time of acquiring new HTs.
The resulting twelve variables were grouped into two categories
named “value” and “risk.” Value variables refer to HT-related
clinical and patient implications, while risk variables include
those that consider the impact of the new HT on the hospi-
tal management dimension. Table 1 shows these 12 variables
together with their definitions.
When a new HT is under consideration for acquisition in a
given healthcare system, decision makers at different levels (i.e.
macro, micro level) may assign dissimilar relevance (hereafter
called “weight”) to the risk and value variables assessed. As
an example, hospital managers may attribute a higher weight
to budget impact in their decision than national-level payers
would. So as to identify potential weight differences and
ascertain the final weight for each of the variables in our study,
we designed a specific questionnaire. Respondents were asked
to score on a Likert scale (from 1 = low importance to 9 =
very important) the weight attributed to each of the twelve
variables mentioned above (Table 1). To test its validity, the
questionnaire was discussed with professionals working at
the Information, Assessment and Quality Agency (AIAQS is
the HTA Agency of the Catalan Ministry of Health [MoH]),
and with a range of professionals working in our hospital.
The questionnaire was then refined according to the comments
received. The final version of the questionnaire was sent to a
convenience sample of twenty-eight key decision makers in the
healthcare system representing two decision-making levels:
(a) national/regional (eight of them working in the Catalonian
MoH planning and management department; seven working in
the seven HTA Agencies/units in Spain – AETS, Lain Entralgo,
AETSA, AVALIA-T, AIAQS, OSTEBA and the HTA Unit of
the Canary Islands MoH) and (b) local (thirteen working at our
hospital - ten Clinical Institutes Directors and three members of
the Hospital Executive Committee). All twenty-eight decision
makers were asked to attribute a weight (from 1 to 9) to each
of the twelve variables selected. Non-normal data distributions
461 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 28:4, 2012
Sampietro-Colom et al.
were observed and the median and interquartile ranges were
estimated for each variable using SPSS 17.0. Statistical differ-
ences among the weights assigned by the two groups of decision
makers were investigated using the Mann-Whitney U test.
The estimated median weights of each of the twelve variables
constitute the first layer in the software program. Participants’
level of agreement regarding the weights assigned to the twelve
variables was explored using a correlation matrix, strong clus-
tering suggesting a high level of agreement among participants,
while wide dispersion suggested a low level of agreement.
The second layer in the computer program includes the re-
sults obtained by performing a mini-HTA for each of the new
HTs assessed. This second layer consists of providing a score
to each of the twelve value and risk variables for the new HTs,
as compared with the technology currently used (i.e., compara-
tor). The score assigned could be (a) higher, (b) equal (if no
differences were observed, or a conclusive answer could not be
obtained due to the nature of the evidence), (c) not available
(when no information regarding the variable was found), or (d)
lower. An algorithm combining the results of the two layers
was developed to obtain an overall score for the new HT under
assessment. In the algorithm, the weight given to each of the
twelve variables is named W (W, i.e., mean values from 1 to 9),
and the results from the comparison between the newHT and the
currently available alternative through the mini-HTA are called
scores (S) (i.e., new versus comparator for each mini-HTA cri-
teria, Higher = 1; Equal = 0; Not Available = 0; Lower =
−1) . The algorithm reads as follows: Overall Score = Risk
point value (R) + Value point value (V) = [W∗S(Staff impact)
+W∗S(Physical Space Impact)+W∗S(Process of care impact)
+W∗S(Incremental cost)+W∗S(Net cost)+W∗S(Investment
effort)]+ [W∗S(Safety)+W∗S(Clinical Benefit)+W∗S(Cost-
Effectiveness) +W∗S(Patient Impact) +W∗S(Quality of Evi-
dence) +W∗S(Innovativeness)]
We made use of three specific HTs of great interest to our
hospital to test whether the decision support tool discriminated
correctly between competing HTs according to the risks and
benefits variables mentioned above. The mini-HTA processes
performed for each of these HTs followed the methodological
standards established for any HTA systematic review (5). Clin-
ical variables and patient impact were assessed by a systematic
and exhaustive search for evidence, and by rating the selected
evidence using the available quality scales (21). Organizational
and economic variables information was obtained by interview-
ing hospital financial managers and physicians on the impact of
the new HTs. A team of clinicians, managers, and HTA analysts
work together throughout the process and, after a process of de-
liberation, attributed final scores to risk and benefit variables
for the new HT as compared with its comparator.
The specific hospital new HTs assessed were: (a) Gravita-
tional Platelet Separation of GPS-III Biologics Biomet R⃝ based
on platelet-rich plasma (PRP) used in total knee arthroplasty
(TKA), (b) Robot Da Vinci used for prostatectomy, and (c) a
Table 2. Weights Given by Decision-Makers to Value and Risk Variables.
National/ Median
Regional Hospital (Interquartile range)
Variables (N= 14) (N= 13) (N= 27) P-value
VALUE
Safety 9 (8–9) 8 (7–9) 8 (7–9) 0.145
Clinical benefit 8 (8–9) 8 (7–9) 8 (7–8) 0.641
Patient Impact 9 (8–9) 7 (7–8) 8 (7–9) 0.052
Cost-Effectiveness 7.5 (7–8) 8 (8–8) 8 (7–8) 0.238
Quality of Evidence 8 (8–9) 9 (8–9) 8 (8–9) 0.250
Innovativeness 7 (6–7) 7 (7–8) 7 (6–8) 0.317
RISK
Staff requirements 7 (6–8) 6 (6–7) 7 (6–7) 0.072
Physical space Impact 5.5 (3–6) 5 (3–5) 5 (3–6) 0.357
Process of care impact 7 (5–7) 7 (6–7) 7 (6–7) 0.960
Incremental Cost 6 (5–8) 6 (5–7) 6 (5–8) 0.824
Net Cost 6.5 (6–8) 7 (6–8) 7 (6–8) 0.940
Investment Effort 7 (6–7) 6 (6–7) 7 (6–7) 0.546
new generation (programmable) deep brain stimulator (DBS)
for Parkinson’s disease. These HTs were selected as they rep-
resent the portfolio of technologies our hospital provides, that
is, high-cost large-size equipment (Robot Da Vinci); moder-
ately priced, small-size equipment/prosthesis (DBS); low-cost,
small-size product used in a procedure (PRP). Results from the
three mini-HTA reports were entered into the program second
layer and a visual dot plot of the value and risk level for each
HT was generated. The tool was named matrix4value.
RESULTS
We obtained a 100 percent response rate from the decision-
maker survey aimed at assessing the weights for the twelve
selectedmini-HTAvariables. Because no significant differences
were found among the scores fromdecisionmakers, themedians
of all responses were taken as the weights (W) for the program
algorithm. Table 2 shows the median value and interquartile
range for each of the variables obtained from the decision-maker
survey.
The results from the exploratory analysis using the correla-
tionmatrix shows a clear clustering of the data among four of the
variables included within the value dimension (i.e., safety, clin-
ical benefit, cost-effectiveness, and quality of evidence), which
suggests agreement on the weights given by decision makers
to these variables. No clear clustering is observed in the vari-
ables included in the risk category (Supplementary Figure 1,
which can be viewed online at www.journals.cambridge.org/
thc2012062).
The systematic search for scientific evidence performed
for each of the three HTs assessed produced the following
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Figure 1. Matrix4Value: value and risk dot plot.
Table 3. Result from the Mini-HTA for each of the HT Assessed and Deliber-
ative Process (Second Layer Decision-Support Tool).
Platelet rich Surgical Deep brain
Variables plasma1 robot2 stimulation3
Safety Equal High High
Clinical benefit Equal Equal High
Patient Impact N/A∗ N/A High
Cost-Effectiveness N/A Low N/A
Quality of Evidence Low Low High
Innovativeness N/A High High
Staff Requirements N/A High Equal
Physical space Impact Equal High Low
Process of care impact Equal High N/A
Incremental Cost High High High
Net Cost High High High
Investment Effort High High Low
∗N/A. Not Available
1. Comparator: non use of platelet rich plasma for total knee arthroplasty.
2. Comparator: endoscopy surgery
3. Comparator: conventional surgery
results: (i) PRP: five articles (3;8;9;11;19) and one unpublished
article (unpublished data, 2009), (ii) Da-Vinci Robot: three
articles and four evaluation reports of which the most recent
evaluation report was used (14) and (iii) DBS: two articles,
one systematic review, and one clinical practice guideline (17),
which incorporates a comprehensive high quality review of
the evidence including the studies addressed by the mentioned
systematic review; the clinical practice guideline and one article
(published after the appearance of the mentioned guideline
and providing new high quality evidence) were selected (24).
Table 3 shows the results obtained by comparing each new
HT and its available alternative using mini-HTA (mini-HTA
results available upon request to authors) and the subsequent
deliberative process by the mini-HTA team. These results
(i.e., scores) were introduced into the second layer of the
matrix4value program.
Finally, Figure 1 shows how the decision support tool and
algorithm visually discriminates competing HTs according to
their risks and benefits. It shows that DBS is the HT with the
highest value and lowest risk for the hospital, that PPR is a
low value and moderate risk technology, and that the Robot Da
Vinci has an almost neutral value and a high risk for the hos-
pital. Thus, matrix4value presented good visual discrimination
capacity between very different HTs.
DISCUSSION
The matrix4value program developed in our study makes pos-
sible the comparison and discrimination of new competing
and considerably different HTs. This program therefore con-
stitutes a valuable tool for hospital decision makers needing to
make decisions on technology acquisitions under fixed budget
constraints.
The tool makes use of information derived from decision
makers regarding the relative value and risks of competing HTs.
In this respect, previous surveys have highlighted the fact that
the relevance given by decision makers to the different variables
considered when assessing HTs may differ (6). To estimate the
relative weight for each criterion we selected decision makers
at macro and micro (hospital) levels, and explored whether they
assigned different weights according to their decision-making
level. If differences did exist, two overall scores for the sameHT
would be obtained, one of them based on the weights given by
macro decision makers, and another by micro decision makers.
This would probably lead to different (perhaps contradictory)
investment decisions. In our healthcare system, the hospital’s
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budget and the decision to acquire some types of HTs, partic-
ularly big ticket technologies, are made by policy makers at
the macro level. We thus need to ensure that the decision made
at hospital level supported by this tool would be in line with
funding decisions made at macro level. The results from our
study show that the weights given by macro and hospital de-
cision makers to the different value and risk variables largely
coincided. This is not in line with previous findings, which
show that, while the variables most frequently assessed by hos-
pital HTA relate to safety, efficacy/effectiveness, organizational
impact, and budget impact (6), some of these variables (i.e.,
organizational and budget impact) are rarely assessed by na-
tional/regional HTA agencies (18), suggesting that differences
in weights may exists among macro and micro decision mak-
ers. Further research with a larger sample size could elucidate
whether significant differences actually exist.
The matrix of correlations among variables exhibits a clus-
tering of data points in the upper-right corner of the corre-
lation plots. This suggests that decision makers mostly agree
that all variables are important to some extent. Of interest,
variables with a tighter clustering are those included in the
“value” dimension (i.e. safety, clinical benefits, patient impact,
cost-effectiveness, quality of scientific evidence, and innova-
tiveness). This means that weights for the “value” dimension
are consistent among all decision makers. Such strong cluster-
ing is no longer observed among “risk” dimension variables,
which means that decision makers differ more on the weights
given to “risk” dimension variables than on the “value” dimen-
sion variables. This leads us to hypothesize that, when consid-
ering the introduction of a new HT, decision makers tend to
give similar weights to “value” variables, while they differ on
the weight of “risk” variables (i.e. staff requirements, physical
space impact, process of care impact, incremental cost, net cost,
and investment effort).
Weight differences between risk variables do not follow a
trend in the two stakeholder groups, that is, National/Regional
and Hospital. This situation could reflect the well-known risk
attitudes (risk-seeker / risk-averse / risk-neutral) of individuals
(10). Finally, risk trends and weights differ among hospital re-
spondents to the survey. We expected responses from hospital
clinicians and managers to be more homogeneous, particularly
in reference to organizational impact and economic impact vari-
ables, because these are very context-specific and relevant vari-
ables at the hospital level. Our expectations were not met in the
study, maybe as a result of a small sample size of the group or
due to existing differences in risk attitudes.
Regarding the use of mini-HTA reports in assessing invest-
ment decisions at hospital level, Kidholm et al. (13) suggested
that the data provided by such reports might sometimes be
deemed insufficient, especially when information about the se-
lection and interpretation of the clinical literature is missing.
If credible advice were to be used in the acquisition of new
HTs, we would agree it is necessary to guarantee the quality of
mini-HTAs reports. In fact, a valuable matrix4value needs to
be based on high-quality processes and contents information.
The mini-HTA reports undertaken in this study complied with
international quality recommendations and standards for HTA
reports (23).
New decision support tools have recently been developed
for the identification and prioritization of HTs accounting for
obsolescence (2) andmarket introduction (1).Wewere also able
to identify one decision support tool in the literature that allows
for the comparison of the characteristics of different brands of
the same HT (22). However, we were unable to identify any
HTA-based decision support tool that helps in the prioritization
of very different competing HTs. The HTA-based tool devel-
oped here has demonstrated its capacity to visually discriminate
different competing HTs according to their value and risks di-
mensions. This visual display could considerably aid hospital
managers in the deliberations to make decisions on investment
priorities. It is important to mention that this tool is not intended
for use in isolation but to be integrated in the standard evidence-
based decision-making process, where there is usually a debate
involving other issues relevant for the final investment decision
(e.g., total budget, hospital strategies, and priorities).
Decision makers’ preferences may change with time and
context. This decision support tool allows for changes inweights
and results when needed, making it a dynamic tool which facil-
itates the incorporation of new scores as a consequence of new
evidence becoming available on the topic, different contexts and
constraints, and changes in decision-makers’ preferences. This
is a relevant feature because it has been shown that while values
are rather more static measures, preferences are more likely to
change over time (12).
This study has certain limitations. The small sample size
may have precluded detecting statistical differences in variable
weights between the different decision makers (i.e., intergroup
weights). However, ultimately, the validity of the results from
this convenience sample may be guaranteed by its representa-
tiveness of the whole spectrum of decision makers regarding
the introduction of new HTs in our healthcare system. Another
limitation of this study could be the lack of randomization of
respondents. Participantswere selected according to their recog-
nized professional careers and involvement in decision making
at different levels in the healthcare system. This option was
chosen to ensure that responses to the questionnaire were based
on professional experience; therefore, selection bias should not
be of practical importance. It could also be argued that this
tool does not include patients’ views when deciding on weights.
Previous literature (20) has shown that patients tend to give
more weight to those criteria that have a close relation with
patient-related issues (e.g., pain). Because the weight attributed
to patient-related aspects is already high in our study, we un-
derstand this limitation has been minimized here. However, it
is recommended that further qualitative work, including pa-
tients’ views and preferences, should be pursued in the future.
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Finally, another limitation concerns the mini-HTA approach.
Traditionally, systematic reviews are usually performed by two
independent reviewers to ascertain the quality of the review
(5). In the present study, all the mini-HTA reviews were per-
formed by the same researcher. However, the reviewer followed
the international procedures and standards requested for a high
quality HTA (23). A second researcher closely supervised the
work done thus minimizing concerns about the quality of the
mini-HTA reviews.
POLICY IMPLICATIONS
Performing mini-HTAs at hospital level has several advan-
tages. The main advantage is that it makes possible the ap-
plication of HTA methodology and processes in an easy, practi-
cal, and timely way, to support decision makers involved in the
introduction of new HTs. However, direct comparison among
mini-HTA reports can be difficult for hospital decision mak-
ers at the time of prioritizing investments. This tool visually
shows how HTs are placed in a risk-value matrix and thus as-
sistswhen the decision-making process involves competingHTs
previously assessed with mini-HTA, providing more clear-cut
information for the prioritization of HTs investments under the
fixed budget scenarios of a hospital setting.
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